Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Schnyder Corneal Dystrophy. Core disease mechanisms, molecular and cellula...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 17
• Snippets retrieved: 20

Relevant Papers

[1] Case Report of Schnyder Corneal Dystrophy—A Rare Lipid Metabolic Disorder of the Cornea

• Authors: N. Stoyanova, Abdulrahman Imran, Zain Hassan, K. Kraev, Y. Basheva-Kraeva et al.
• Year: 2025
• Venue: Life
• URL: https://www.semanticscholar.org/paper/332581b42c2eac358549c406f695a6774dd24f64
• DOI: 10.3390/life15030409
• PMID: 40141754
• PMCID: 11943904
• Summary: This case illustrates the diagnostic challenges of SCD, particularly in the absence of corneal crystals, a hallmark feature that is not universally present, and highlights the need for multidisciplinary care in SCD management.
• Evidence snippets:
• Snippet 1 (score: 0.599) > Schnyder corneal dystrophy (SCD) is a rare, progressive autosomal dominant disorder that was first described by the Swiss ophthalmologist Franz Schnyder in 1924 [1][2][3]. It has a prevalence estimated at less than 1 in 1,000,000 individuals. It is characterized by bilateral opacification of the cornea due to abnormal accumulation of lipids, primarily cholesterol and phospholipids, within the corneal stroma (Figure 1) [4]. This lipid deposition leads to progressive corneal clouding and visual impairment, often beginning in early adulthood and advancing with age [5]. Clinically, SCD is notable for its variable presentation, ranging from subtle stromal haze to conspicuous crystalline deposits, depending on the stage and severity of the disease [6,7]. > tion leads to progressive corneal clouding and visual impairment, often beginning in early adulthood and advancing with age [5]. Clinically, SCD is notable for its variable presentation, ranging from subtle stromal haze to conspicuous crystalline deposits, depending on the stage and severity of the disease [6,7]. > The genetic basis of SCD was elucidated in 2007, with the identification of mutations in the UBIAD1 gene as the primary causative factor. UBIAD1 encodes a key enzyme that is involved in cholesterol metabolism and vitamin K2 biosynthesis, underscoring the metabolic underpinnings of the disease [8]. However, the exact molecular mechanisms linking UBIAD1 mutations to corneal lipid accumulation remain poorly understood. Dysregulated lipid metabolism is thought to impair corneal transparency, leading to progressive visual decline [9][10][11]. > While traditionally considered a corneal disorder, SCD is increasingly recognized for its potential systemic implications, including dyslipidemia. Advances in imaging modalities, such as optical coherence tomography (OCT) and confocal microscopy, have enhanced the diagnostic accuracy, particularly in cases lacking visible corneal crystals.
• Snippet 2 (score: 0.453) > Case Report of Schnyder Corneal Dystrophy—A Rare Lipid Metabolic Disorder of the Cornea
• Snippet 3 (score: 0.430) > Advances in imaging modalities, such as optical coherence tomography (OCT) and confocal microscopy, have enhanced the diagnostic accuracy, particularly in cases lacking visible corneal crystals. Despite these advancements, treatment options remain limited, with penetrating keratoplasty being reserved for advanced cases [11][12][13][14][15]. > This case underscores the importance of recognizing rare corneal dystrophies such as SCD, particularly in patients with systemic comorbidities or atypical corneal findings. Enhanced clinical awareness and improved diagnostic strategies could facilitate earlier diagnosis, timely management, and better visual outcomes for affected individuals. The genetic basis of SCD was elucidated in 2007, with the identification of mutations in the UBIAD1 gene as the primary causative factor. UBIAD1 encodes a key enzyme that is involved in cholesterol metabolism and vitamin K2 biosynthesis, underscoring the metabolic underpinnings of the disease [8]. However, the exact molecular mechanisms linking UBIAD1 mutations to corneal lipid accumulation remain poorly understood. Dysregulated lipid metabolism is thought to impair corneal transparency, leading to progressive visual decline [9][10][11]. > While traditionally considered a corneal disorder, SCD is increasingly recognized for its potential systemic implications, including dyslipidemia. Advances in imaging modalities, such as optical coherence tomography (OCT) and confocal microscopy, have enhanced the diagnostic accuracy, particularly in cases lacking visible corneal crystals. Despite these advancements, treatment options remain limited, with penetrating keratoplasty being reserved for advanced cases [11][12][13][14][15]. > This case underscores the importance of recognizing rare corneal dystrophies such as SCD, particularly in patients with systemic comorbidities or atypical corneal findings. Enhanced clinical awareness and improved diagnostic strategies could facilitate earlier diagnosis, timely management, and better visual outcomes for affected individuals. > Life 2025, 15, 409 3 of 8

[2] An Arg124His mutation in TGFBI associated to Avellino corneal dystrophy in a Chinese pedigree

• Authors: Zhensheng Gu, Peiquan Zhao, G. He, C. Wan, Gang Ma et al.
• Year: 2011
• Venue: Molecular Vision
• URL: https://www.semanticscholar.org/paper/1a83983671140b413929af8e0f143bf0554b6023
• PMID: 22194646
• PMCID: 3244477
• Citations: 9
• Summary: This study demonstrated that a G>A transition in Arg124His of TGFBI was responsible for Avellino corneal dystrophy in a Chinese pedigree, which further supports the importance of T GFBIp in maintaining transparency of the cornea.
• Evidence snippets:
• Snippet 1 (score: 0.570) > The challenge to ophthalmologists and researchers is to correctly diagnose and classify corneal dystrophies, as well as to understand their phenotype-genotype aspects. In 2008, a useful nomenclature for corneal dystrophies was established by the International Committee on the Classification of Corneal dystrophies (IC3D) based on traditional clinical examination and advances in molecular genetics. Under the IC3D classification system, each dystrophy has a detailed description including an OMIM number, eponyms, genetic loci, relevant genes, onset, signs, symptoms, histopathology, etc., combining clinical features and genetic characteristics including molecular mechanism and protein functions [5][6][7]. > In this study, we recruited a Chinese four-generation pedigree affected by corneal dystrophy and identified the gene mutation responsible for the disease. We hope our study will provide an insight into the mechanisms of the disease.

[3] Atypical Regressive Corneal Endothelial Cysts in Long-Term Confocal Follow-Up

• Authors: A. Smedowski, E. Wylęgała, L. Wójcik, D. Tarnawska
• Year: 2015
• Venue: Medicine
• URL: https://www.semanticscholar.org/paper/6b567579bbf916d4f69a5a083f090f5e7dba4b0d
• DOI: 10.1097/MD.0000000000000564
• PMID: 25738472
• PMCID: 4553953
• Summary: The presented case is an example of an unusual corneal endothelial syndrome with probably nondystrophic background due to observed dynamic state with regressive tendency.
• Evidence snippets:
• Snippet 1 (score: 0.548) > T he term ''dystrophy'' is commonly used to describe an inherited disorder, fulfilling certain criteria. In ophthalmology, the term ''corneal dystrophy'' has no strictly defined borders. It is a group of corneal disorders usually with the following features: inherited, noninflammatory, typically bilateral, symmetric, slowly progressive (regression in dystrophy development is unusual), and without relationship to environmental or systemic factors. 1 However, in some cases corneal dystrophies can coexist with other systemic disabilities (macular dystrophy or amyloidosis, which is often called lattice dystrophy type II, Schnyder dystrophy) or can develop unilateral (posterior polymorphous endothelial dystrophy). On the other hand, there are some corneal abnormalities which are excluded from the corneal dystrophies group, despite fulfilling defined conditions (such as ''cornea plana''-inherited, bilateral, usually not related to systemic abnormalities). 2 Corneal endothelial dystrophies concern diseases characterized by corneal endothelial cells layer abnormalities, what usually leads to slowly progressive degeneration of corneal endothelium, decreasing of cells density and affecting visual acuity. 3 n the contrary, there are nondystrophic endothelial syndromes that include variants of iridocorneal endothelial syndromes (ICE) and endothelial (preendothelial) deposits. In such cases, changes might be observed unilaterally with tendency for both progression and regression while they are secondary pronunciation of other eye disorders (inflammatory changes, iris and iridocorneal angle pathologies, iatrogenic repercussion). 4,5 he aim of this report is to describe abnormal phenotype of corneal endothelium in a 36-year-old patient, with features of clinical regression accompanied by progressive endothelial pathology.

[4] Evaluation of the Genetic Variation Spectrum Related to Corneal Dystrophy in a Large Cohort

• Authors: Wei Li, N. Qu, Jian-kang Li, Yu-Xin Li, Dong Han et al.
• Year: 2021
• Venue: Frontiers in Cell and Developmental Biology
• URL: https://www.semanticscholar.org/paper/e08001759aede393322d1ef0f4e90cc8d18ccb36
• DOI: 10.3389/fcell.2021.632946
• PMID: 33816482
• PMCID: 8012530
• Citations: 12
• Influential citations: 1
• Summary: The genetic landscape and mutation spectrum of patients with corneal dystrophies (CDs) in a large Han ethnic Chinese Cohort with inherited eye diseases (IEDs) is characterized and the variation spectrum of 22 CD-related genes is systematically described.
• Evidence snippets:
• Snippet 1 (score: 0.509) > Corneal dystrophies (CDs) are genetically heterogeneous disorders characterized by the gradual accumulation of deposits within different corneal layers, resulting in changes in corneal transparency and refractive index (Bron, 1990). > Clinically, these diseases are divided into anatomical categories according to the specific corneal layer involved. According to the current International Committee for Classification of Corneal Dystrophies (IC3D), CDs can be divided into 4 categories and 22 subcategories. CDs can classify into one of the following anatomical categories (Weiss et al., 2008(Weiss et al., , 2015)): (a) epithelial and subepithelial CDs; (b) epithelial-stromal transforming growth factor-beta-induced protein (TGFBI) CDs; (c) stromal CDs; and (d) endothelial CDs. At present, corneal transplants are the most effective method for the treatment of CDs. Due to lack of clinical symptoms, some patients may be misdiagnosed before phototherapeutic keratectomy (PTK) treatment or neglected before refractive surgery, which highlights the urgent need to understand the disease mechanism of CDs (Zeng et al., 2017). > Genetically, CDs are autosomal dominant, autosomal recessive or X-linked modes. Autosomal dominant inheritance accounts for most cases and is accompanied by a high degree of penetrance (Pieramici and Afshari, 2006). To date, studies have identified disease-causing mutations in 18 genes associated with CDs, many of which have established genotype-phenotype associations.
• Snippet 2 (score: 0.456) > To date, studies have identified disease-causing mutations in 18 genes associated with CDs, many of which have established genotype-phenotype associations. For example, mutations in six genes (CHST6, OMIM 605294; UBIAD1, OMIM 611632; SLC4A11, OMIM 610206; PIKFYVE, OMIM 609414; TACSTD2, OMIM 137290; DCN, and OMIM 125255) have found a direct genetic association with macular corneal dystrophies (MCD), Schnyder CD (SCD), congenital hereditary endothelial dystrophy (CHED), fleck CD (FCD), gelatinous drop-like CD (GDLD), and congenital stromal CD (CSCD), respectively, (Zhang et al., 2013). At the same time, there are significant heterogeneities in distinct mutations of the same gene. For instance, according to the second edition of IC3D, five distinct TGFBI mutations (p.R124H, p.R555W, p.R124C, p.R555Q, and p.R124L) cause different types of CDs, including Granular corneal dystrophy, type 2; Granular corneal dystrophy, type 1; Lattice corneal dystrophy, type 1 (LCD1); Thiel-Behnke corneal dystrophy (TBCD); and Reis-Bücklers corneal dystrophy, respectively, (Weiss et al., 2008(Weiss et al., , 2015)). > Panel-based targeted exon sequencing has proven to have excellent performance in the molecular diagnosis of heterogeneous genetic diseases. Studies have confirmed that targeted enrichment based on multi-gene panels are highly sensitive, accurate, and reproducible (Adams and Eng, 2018). A comprehensive overview of the genetic landscape associated with the CD phenotype have been provided based on sequencing hundreds of potentially related disease-causing genes.

[5] Case report: A case of corneal deposits between binocular descemet membrane and corneal endothelial layer after small-incision lenticule extraction (SMILE) followed by HPV vaccine

• Authors: Hao Zhang, Yingping Deng, Ke Ma, Chengshu Sun, Jing Tang
• Year: 2022
• Venue: Frontiers in Medicine
• URL: https://www.semanticscholar.org/paper/0789d476b0e8b9ba5ee04537e6b64258a801025c
• DOI: 10.3389/fmed.2022.1042405
• PMID: 36619641
• PMCID: 9811408
• Summary: There are two possible causes of corneal changes in patients: the first is IGA elevation caused by vaccination, deposited in the cornea, and the ARSG gene mutation of the patient leads to a potential congenital corneAL dystrophy, and clinical manifestations occur under the stimulation of the vaccine.
• Evidence snippets:
• Snippet 1 (score: 0.505) > There are currently two kinds of reported diseases of congenital corneal dystrophy similar to the corneal changes in our case. > (1) Schnyder corneal dystrophy disease (SCD). The clinical characteristics of SCD are the deposition of cholesterol and phospholipids in the subepithelium and in the stroma of the cornea, resulting in corneal opacity (10)(11)(12)(13). The specific clinical manifestations are as follows: (1) It is an autosomal dominant genetic disease with a high degree of extrinsic dominance, so there is often a family history ( 14). ( 2) The disease usually starts at about 20 years old, and a few can be 10 years younger (15). ( 3) Often binocular disease, the degree of corneal turbidity increases with age, so the vision is progressive decline, there may be glare and photophobia (16). ( 4) Limbal lipid opacity resembles cornea arcus senilis (16). ( 5) About 54% of SCD patients had crystalline deposition of cholesterol in the cornea ( 16). ( 6) About 4% of SCD patients have genu valgus, spinal and finger malformations and other signs. ( 7) About 66% of SCD patients had dyslipidemia (16-19). ( 8) The pathogenesis of SCD may be related to local lipid metabolism defects caused by UBIADI gene mutation, but the exact mechanism is not clear (11, 13, 14). ( 2) Pre-descemet corneal dystrophy (PDCD) is a rare form of stromal dystrophy of the cornea characterized by dense, irregular deposits of opaque material between the deep stromal layer and the descemet membrane and associated with mutations in the STS gene (20). PDCD has several subgroups, which may represent sporadic, age-related, or degenerative changes (21). The symptoms of PDCD patients are mild, and their vision is generally not affected (22).

[6] Pathogenesis and treatments of TGFBI corneal dystrophies.

• Authors: K. Han, Seung-Il Choi, Tae-im Kim, Yong-Sun Maeng, R. Stulting et al.
• Year: 2016
• Venue: Progress in retinal and eye research
• URL: https://www.semanticscholar.org/paper/4133399eafb3c6754d8fb5fba5de42f66fc2b5cd
• DOI: 10.1016/j.preteyeres.2015.11.002
• PMID: 26612778
• Citations: 107
• Influential citations: 10
• Summary: The current knowledge of TGFBI corneal dystrophies including clinical manifestations, epidemiology, most common and recently reported associated mutations for each disease, and treatment modalities are summarized.
• Evidence snippets:
• Snippet 1 (score: 0.501) > Transforming growth factor beta-induced (TGFBI) corneal dystrophies are a group of inherited progressive corneal diseases. Accumulation of transforming growth factor beta-induced protein (TGFBIp) is involved in the pathogenesis of TGFBI corneal dystrophies; however, the exact molecular mechanisms are not fully elucidated. In this review article, we summarize the current knowledge of TGFBI corneal dystrophies including clinical manifestations, epidemiology, most common and recently reported associated mutations for each disease, and treatment modalities. We review our current understanding of the molecular mechanisms of granular corneal dystrophy type 2 (GCD2) and studies of other TGFBI corneal dystrophies. In GCD2 corneal fibroblasts, alterations of morphological characteristics of corneal fibroblasts, increased susceptibility to intracellular oxidative stress, dysfunctional and fragmented mitochondria, defective autophagy, and alterations of cell cycle were observed. Other studies of mutated TGFBIp show changes in conformational structure, stability and proteolytic properties in lattice and granular corneal dystrophies. Future research should be directed toward elucidation of the biochemical mechanism of deposit formation, the relationship between the mutated TGFBIp and the other materials in the extracellular matrix, and the development of gene therapy and pharmaceutical agents.

[7] Update on the genetics of corneal endothelial dystrophies

• Authors: C. Kannabiran, S. Chaurasia, Muralidhar Ramappa, V. Mootha
• Year: 2022
• Venue: Indian Journal of Ophthalmology
• URL: https://www.semanticscholar.org/paper/3080a90259e7d8e711648196c9dbb44611bdc589
• DOI: 10.4103/ijo.IJO_992_22
• PMID: 35791103
• PMCID: 9426112
• Citations: 17
• Summary: Knowledge of the genetics of corneal endothelial dystrophies has considerably advanced within the last decade and has contributed to better diagnosis of these dystrophic diseases as well as opened up the possibility of novel therapeutic approaches based on the molecular mechanisms involved.
• Evidence snippets:
• Snippet 1 (score: 0.485) > Many recent advances in the genetics of corneal endothelial dystrophies have brought to light pathways and mechanisms underlying the development of these diseases and pointed to correlations between genotype and phenotype. Despite a high degree of genetic heterogeneity, particularly for PPCD and FECD, the prevalence of mutations in the existing genes are rapidly being defined in patients from different regions. The application of genome sequencing may further facilitate the identification of new loci or novel types of pathogenic changes in existing genes in the near future and enhance our understanding of the underlying genetics of these diseases. A significant corollary of the new developments in the field lies in the possibility of developing suitable new therapies for these disorders based on their known genetic and molecular mechanisms. Proof of concept has already been obtained for using specific approaches to inhibit the triplet repeat expansionmediated disease pathways in FECD. Genetic screening may aid in establishing a genotype-phenotype correlation for patients. In a majority of cases, a meticulous slit-lamp examination and histological analysis wherever available help in determining the exact nature of the endothelial disease, although a diagnosis in patients with unusual manifestations can be supported by genetic testing. In familial forms of PPCD, knowing the mutation can aid in early screening and detection of affected but asymptomatic individuals. Developments in genetics have improved our knowledge of the corneal endothelial dystrophies and reduced the inaccuracies in their nomenclature. An accurate diagnosis of the specific type of endothelial dystrophy assists in planning the most appropriate management strategy and prognostication of the clinical condition. Furthermore, with the advent of alternatives such as pharmacotherapy and targeted molecular therapy in the management of endothelial dystrophies, a precise diagnosis of the clinical phenotype has become increasingly paramount.

[8] Ocular Involvement in Hereditary Amyloidosis

• Authors: A. Minnella, R. Rissotto, E. Antoniazzi, M. Di Girolamo, M. Luigetti et al.
• Year: 2021
• Venue: Genes
• URL: https://www.semanticscholar.org/paper/760dd2f506df9afdd3db36a6fd1ce28bd189aaf1
• DOI: 10.3390/genes12070955
• PMID: 34206500
• PMCID: 8304974
• Citations: 64
• Summary: This review aims at describing the main biochemical, histopathological and clinical features of systemic amyloidosis associated with eye involvement, with particular emphasis on the inherited forms.
• Evidence snippets:
• Snippet 1 (score: 0.480) > The role of KE gene mutations in human chromosome 5q31 has been unequivocally established by molecular genetics as causative for corneal dystrophies, but nevertheless, the pathogenic mechanisms responsible for abnormal protein aggregation still need to be clarified [100]. > The molecular analysis of KE-related corneal dystrophies revealed deposits of abnormal protein in the forms of amyloid fibrils and/or nonamyloid amorphous aggregations. > Population analyses have revealed two hot spots for mutations, Arg-124 and Arg-555, associated with corneal dystrophies. In the Arg-124 mutation, four different mutations give rise to four different phenotypes. The Arg124Cys mutation has been linked with lattice corneal dystrophy type 1, granular corneal dystrophy type 2, granular corneal dystrophy type 3 and a variant of granular corneal dystrophy type 1 [100]. > Mutations of KE cause hereditary corneal dystrophies that are characterized by the abnormal deposition of amyloid fibrils and/or granular aggregation in the cornea and have been linked to at least 13 clinically and histopathologically distinct autosomal dominant corneal dystrophies. Amyloid deposits are found in many corneal dystrophies, including lattice dystrophy (LCD) type I, IA, II, IIIA, IIIB, IV, V, VI and VII and granular dystrophy type II, also called Avellino dystrophy [99]. > Regarding differential diagnosis, along with the primary amyloid deposits, a variety of ocular diseases can develop secondary amyloid deposits, namely trachoma, lepra, sarcoidosis, interstitial keratitis, phlyctenular keratitis, uveitis, chronic post-traumatic inflammation, glaucoma, keratoconus and retinopathy of prematurity. Recently, point mutations in the transforming growth factor-β-induced gene (TGFBI) encoding for the protein KE have been found to be associated with these corneal diseases [99].

[9] The Sociodemographic and Risk Factors for Fuchs’ Endothelial Dystrophy: A Nationwide, Matched Case–Control Study in Taiwan

• Authors: Yuh-Shin Chang, Chung‐Han Ho, Jhi-Joung Wang, S. Tseng, Ren-Long Jan
• Year: 2022
• Venue: Journal of Personalized Medicine
• URL: https://www.semanticscholar.org/paper/3aa8aeb16188d0d89b3d5083336df4ba1c705bb7
• DOI: 10.3390/jpm12020305
• PMID: 35207793
• PMCID: 8877330
• Citations: 2
• Summary: It is found that more than half of the FED patients in Taiwan were aged ≥45 years old, there was an equal female-to-male ratio (1.06:1), and patients with a lower income and living in northern Taiwan had higher odds of developing FED.
• Evidence snippets:
• Snippet 1 (score: 0.464) > Fuchs' corneal endothelial dystrophy (FED), the most common form of corneal dystrophy, affects the endothelium, which is the innermost layer of the cornea. FED is characterized by endothelial cell density reduction with endothelium cell morphology alterations including variation in cell shape, known as cellular pleomorphism, and variation in the cell size, known as polymegathism [1]. FED usually presents in the fifth decade of life and progresses over the next two to three decades with continued endothelium cell loss and dysfunction. Some FED patients may be asymptomatic in the early stages of the disease, but patients may have glare or reduced visual acuity, severe pain due to the corneal edema progression to stromal thickness, increased bulla formation, or even long-standing corneal vascularization [2]. > FED is a multifactorial disorder caused by a complex combination of genetic, biochemistry, biology, and environmental factors. The pathophysiology of FED remains unknown, although several proposed mechanisms have been reported [1,[3][4][5]. Channelopathy, related to mutations in the genes of the ion channels in the corneal endothelium appears to be an important pathogenetic factor in the development of FED [3,4]. Elevation of oxidative stress and reactive oxygen species accumulation could lead to apoptosis of endothelial cells and is also regarded as one major cause of the development of FED [1,4]. The epithelialmesenchymal transition, in which fibroblastic or epithelial cell phenotypes transform from endothelial cells, could result in the secretion of extracellular matrix proteins leading to abnormal deposition, is thought to be involved in the pathogenesis of FED [1,4,5]. > The estimated incidence and prevalence of FED varies greatly worldwide, with a higher prevalence in Europe and the USA and lower rates in Asia, possibly because of different genetic or environmental factors and a difference in clinical definitions of FED [6,7]. Being older than 40 years of age is a major risk factor for FED development [4,5,8].

[10] Genetic mutations and molecular mechanisms of Fuchs endothelial corneal dystrophy

• Authors: Xue Liu, Tao Zheng, Chuchu Zhao, Yi Zhang, Hanruo Liu et al.
• Year: 2021
• Venue: Eye and Vision
• URL: https://www.semanticscholar.org/paper/12e7cdcdc924d1fde2012ef77fd55d89c3d6957d
• DOI: 10.1186/s40662-021-00246-2
• PMID: 34130750
• PMCID: 8204469
• Citations: 26
• Influential citations: 2
• Summary: The mutations of COL8A2, TCF4 , TCF8 , SLC4A11 and AGBL1 genes in Fuchs endothelial corneal dystrophy are summarized and several potential treatments related to the pathogenesis of Fuchs vascular disease are discussed.
• Evidence snippets:
• Snippet 1 (score: 0.456) > Background Fuchs endothelial corneal dystrophy is a hereditary disease and the most frequent cause of corneal transplantation in the worldwide. Its main clinical signs are an accelerated decrease in the number of endothelial cells, thickening of Descemet’s membrane and formation of guttae in the extracellular matrix. The cornea’s ability to maintain stromal dehydration is impaired, causing painful epithelial bullae and loss of vision at the point when the amount of corneal endothelial cells cannot be compensated. At present, apart from corneal transplantation, there is no other effective treatment that prevents blindness. Main text In this review, we first summarized the mutations of COL8A2 , TCF4 , TCF8 , SLC4A11 and AGBL1 genes in Fuchs endothelial corneal dystrophy. The molecular mechanisms associated with Fuchs endothelial corneal dystrophy, such as endoplasmic reticulum stress and unfolded protein response pathway, oxidative stress, mitochondrial dysregulation pathway, apoptosis pathway, mitophagy, epithelial-mesenchymal transition pathway, RNA toxicity and repeat-associated non-ATG translation, and other pathogenesis, were then explored. Finally, we discussed several potential treatments related to the pathogenesis of Fuchs endothelial corneal dystrophy, which may be the focus of future research. Conclusions The pathogenesis of Fuchs endothelial corneal dystrophy is very complicated. Currently, corneal transplantation is an important method in the treatment of Fuchs endothelial corneal dystrophy. It is necessary to continuously explore the pathogenesis of Fuchs endothelial corneal dystrophy and establish the scientific foundations for the development of next-generation corneal therapeutics.

[11] Systematic Ocular Phenotyping of Knockout Mouse Lines Identifies Genes Associated With Age-Related Corneal Dystrophies

• Authors: Andrew Briere, P. Vo, Benjamin Yang, David J. Adams, Takanori Amano et al.
• Year: 2025
• Venue: Investigative Ophthalmology & Visual Science
• URL: https://www.semanticscholar.org/paper/ff217a6c3bd93ff3465693742f74ebdd4ef549f3
• DOI: 10.1167/iovs.66.5.7
• PMID: 40323269
• PMCID: 12060066
• Citations: 1
• Summary: This study identified 14 genes linked to LACD in knockout mice, 12 of which are novel in corneal biology and may serve as potential therapeutic targets for treating corneal diseases in aging human populations.
• Evidence snippets:
• Snippet 1 (score: 0.451) > Purpose This study investigates genes contributing to late-adult corneal dystrophies (LACDs) in aged mice, with potential implications for late-onset corneal dystrophies (CDs) in humans. Methods The International Mouse Phenotyping Consortium (IMPC) database, containing data from 8901 knockout mouse lines, was filtered to include late-adult mice (49+ weeks) with significant (P < 0.0001) CD phenotypes. Candidate genes were mapped to human orthologs using the Mouse Genome Informatics group, with expression analyzed via PLAE and a literature review for prior CD associations. Comparative analyses of LACD genes from IMPC and established human CD genes from IC3D included protein interactions (STRING), biological processes (PANTHER), and molecular pathways (KEGG). Results Analysis identified 14 genes linked to late-adult abnormal corneal phenotypes. Of these, 2 genes were previously associated with CDs in humans, while 12 were novel. Seven of the 14 genes (50%) were expressed in the human cornea based on single-cell transcriptomics. Protein–protein interactions via STRING showed several significant interactions with known human CD genes. PANTHER analysis identified six biological processes shared with established human CD genes. Two genes (Rgs2 and Galnt9) were involved in pathways related to human corneal diseases, including cGMP-PKG signaling, mucin-type O-glycan biosynthesis, and oxytocin signaling. Other candidates were implicated in pathways such as pluripotency of stem cells, MAPK signaling, WNT signaling, actin cytoskeleton regulation, and cellular senescence. Conclusions This study identified 14 genes linked to LACD in knockout mice, 12 of which are novel in corneal biology. These genes may serve as potential therapeutic targets for treating corneal diseases in aging human populations.

[12] Systematic ocular phenotyping of 8,707 knockout mouse lines identifies genes associated with abnormal corneal phenotypes

• Authors: P. Vo, Denise M. Imai-Leonard, Benjamin Yang, Andrew Briere, Andy Shao et al.
• Year: 2025
• Venue: BMC Genomics
• URL: https://www.semanticscholar.org/paper/27f14f70a1aee24427e12604879b43dd4ad247ab
• DOI: 10.1186/s12864-025-11222-8
• PMID: 39833678
• PMCID: 11744888
• Citations: 3
• Summary: This study identified 213 mouse genes that resulted in statistically significant abnormal corneal phenotypes in knockout mice, many of which have not previously been implicated in corneal pathology, and identified other possible underappreciated mechanisms relevant to the human cornea.
• Evidence snippets:
• Snippet 1 (score: 0.450) > Corneal dysmorphologies (CDs) are typically classified as either regressive degenerative corneal dystrophies (CDtrs) or defective growth and differentiation-driven corneal dysplasias (CDyps). Both eye disorders have multifactorial etiologies. While previous work has elucidated many aspects of CDs, such as presenting symptoms, epidemiology, and pathophysiology, the genetic mechanisms remain incompletely understood. The purpose of this study was to analyze phenotype data from 8,707 knockout mouse lines to identify new genes associated with the development of CDs in humans. 8,707 knockout mouse lines phenotyped by the International Mouse Phenotyping Consortium were queried for genes associated with statistically significant (P < 0.0001) abnormal cornea morphology to identify candidate CD genes. Corneal abnormalities were investigated by histopathology. A literature search was used to determine the proportion of candidate genes previously associated with CDs in mice and humans. Phenotypes of human orthologues of mouse candidate genes were compared with known human CD genes to identify protein-protein interactions and molecular pathways using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), Protein Analysis Through Evolutionary Relationships (PANTHER), and Kyoto Encyclopedia of Genes and Genomes. Analysis of data from 8,707 knockout mouse lines identified 213 candidate CD genes. Of these, 37 (17%) genes were previously known to be associated with CD, including 14 in the mouse, 16 in humans, and 7 in both. The remaining 176 (83%) genes have not been previously implicated in CD. We also searched publicly available RNAseq data and found that 131 of the total 213 (61.5%) were expressed in adult human corneal tissue. STRING analysis showed several interactions within and between candidate and established CD proteins. All cellular pathways of the established genes were found in the PANTHER analysis of the candidate genes. Several of the candidate genes were implicated in corneal disease, such as TGF-ß signaling. We also identified other possible underappreciated mechanisms relevant to the human cornea. We identified 213 mouse genes that resulted in statistically significant abnormal corneal phenotypes in knockout mice, many of which have not

[13] TGFBI gene mutation analysis in a Chinese pedigree of Reis-Bücklers corneal dystrophy

• Authors: Ke Ma, Guo Liu, Yin Yang, Man Yu, R. Sui et al.
• Year: 2010
• Venue: Molecular Vision
• URL: https://www.semanticscholar.org/paper/a22756ae29fd2c344106a9957ef100cd6084cb04
• PMID: 20360992
• PMCID: 2847680
• Citations: 15
• Summary: The R124C mutation in TGFBI is also found to be responsible for RBCD, along with G623D and R124L, which is a known mutation for lattice corneal dystrophy type I.
• Evidence snippets:
• Snippet 1 (score: 0.450) > Corneal dystrophy is a group of diseases with autosomal dominant inheritance.Until now, corneal dystrophies failed to be clearly classified because of the variability in phenotypic expression of the diseases.A proposed corneal dystrophy classification system, which is identical or similar to those in the current nomenclature, is anatomically based with dystrophies classified according to the layer mainly involved, such as the epithelial and subepithelial, Bowman's layer, stroma, Descemet's membrane, and endothelium [16].Clinical characteristics such as the depth of the cornea affected, the morphology of the deposits, and the histopathological features are also important for classifying different corneal dystrophies [17].However, dystrophies with overlapping and atypical characteristics are still too similar to be distinguished from one another.A Chinese family with atypical RBCD was recently reported [14].This family presented with a unique corneal dystrophy within the Bowman's layer and the corneal stroma.However, no lattice was noted in the proband or other affected members, and the deposits were located in the mid-stroma of the cornea, which was different from the phenotypes previously reported in lattice corneal dystrophy patients with R124C mutation.Some corneal dystrophies affect multiple corneal layers and therefore cannot be classified as a single type based on morphologic criteria. > Phenotypically, the pedigree we documented here exhibited typical features of RBCD.The affected individuals presented with a gray-white geographic opacity in the anterior to mid-stroma of both eyes.In addition, geometric and round opacities in the subepithelial layers and anterior to mid-stroma were found in all of the affected family members.The clinical features, including recurrent erosion and gradually developing opacities of the Bowman's layer, were consistent with the characteristic of RBCD [1,18] and to those found in the families previously described by Afshari et al. [10] and Aldave et al. [19].

[14] Corneal cell therapy: with iPSCs, it is no more a far-sight

• Authors: Koushik Chakrabarty, R. Shetty, Arkasubhra Ghosh
• Year: 2018
• Venue: Stem Cell Research & Therapy
• URL: https://www.semanticscholar.org/paper/5528565bd93ce92ce3b62c947ccbaec04a2c8d3a
• DOI: 10.1186/s13287-018-1036-5
• PMID: 30359313
• PMCID: 6202849
• Citations: 64
• Influential citations: 1
• Summary: This review discusses and summarizes protocols that have been devised so far to direct differentiation of human pluripotent stem cells (hPSCs) to different corneal cell phenotypes and intends to facilitate an understanding which would allow developing efficient and robust protocols to obtain specific cornean cell phenotype from hPSCs.
• Evidence snippets:
• Snippet 1 (score: 0.445) > Subsequently, Utheim et al. [22] found that storage temperature also affects the gene expression pattern of the cultured human oral keratinocytes. Here, it is crucial to note that the authors observed storage temperature influencing the expression of genes involved in both the proliferation and differentiation process of oral keratinocytes extending its significance in the field. The lower survival rate of the transplanted oral epithelia in the corneal limbal regions [19] is further accentuated by the duration of storage of cultured LESCs and oral keratinocytes limiting its availability for repeat transplants which is often necessary to address some of the LESC-related corneal surface diseases. These challenges can be addressed using iPSCs which can be stored effectively upon their generation and directed to LESCs and CEC phenotype when required. Efforts towards obtaining LESCs from iPSCs have provided good results [24] thereby placing iPSCs as a promising source of transplantable LESCs. Another common affliction of the cornea is the corneal dystrophies (CD) which typically have a genetic etiology [25] and often with no options for therapy other than keratoplasty in advanced cases. Corneal diseases such as the dystrophies are a persisting global health concern with a significant economic burden since there are very limited drug-based treatments available. In addition, there are problems of graft rejection, or the transplanted tissue also being affected with the disease as the underlying cause for the pathology has not been addressed. However, for many of the CDs, the cellular signaling mechanisms involved in their pathology are still elusive. Although studies [26] have demonstrated the formation and accumulation of the mutated gene products (proteins) in most of the corneal dystrophies, little is known about the contextual molecular mechanisms involved in the formation of such deposits. Therefore, understanding the cellular context and relevant mechanisms involved in corneal dystrophy is imperative for identifying possible therapeutic interventions. Differentiation protocols continue to improve leading to robust generation of corneal cells from iPSCs, thereby providing the necessary platform to model the corneal diseases and its utilization in cell replacement therapy.

[15] Macular dystrophies associated with Stargardt-like phenotypes

• Authors: R. A. S. Amaral, Olivia Araújo Zin, M. V. Salles, F. Motta, J. Sallum
• Year: 2023
• Venue: Arquivos Brasileiros de Oftalmologia
• URL: https://www.semanticscholar.org/paper/87b1b56d8b2886a9853c330997c5e59ddf505221
• DOI: 10.5935/0004-2749.2021-0415
• PMID: 36995812
• PMCID: 11619082
• Citations: 2
• Summary: Macular dystrophies may have phenotypic similarities to Stargardt-like phenotype associated with other genes besides the classic ones, and these genes may be associated with pathogenic variants related to the phenotypes.
• Evidence snippets:
• Snippet 1 (score: 0.435) > The pharmacological modulation of the visual cycle serves as a novel approach to the potential treatment of degenerative retinal diseases. Finding the involved genes in the phenotypes leads to new possibilities of discovering treatments by increasing or decreasing the function on the metabolic pathways of those genes. As the pathophysiology of STGD1 is complex, a multitargeted approach could help in the identification of alternative pathways or modification factors involving the disease mechanism. > In this report of four patients with macular dystrophy and history suggesting Stargardt-like disease, two patient's phenotypes were related to AD genes (RIMS1 and CRX) and those of the other two patients were related to AR genes (CRB1 and RDH12). STGD1 is the most common inherited macular dystrophy but has a wide clinical spectrum, and several inherited macular dystrophies have phenotypic similarities that can make clinical diagnosis challenging. As the disease progress, clinical appearance may change over time, and its end-stage appearance of diffuse atrophy and peripheral involvement are almost indistinguishable from each other. Functional tests are still important for the characterization of the phenotype and help in the diagnostic definition, especially in cone dystrophies, which are often the main differential diagnosis for STGD1. > Molecular genetic studies and detailed clinical descriptions have demonstrated that a central atrophic lesion with surrounding subretinal yellow flecks can arise secondary to mutations in different genes. With the improvement of potential treatments for inherited retinal dystrophies, correct molecular diagnosis is essential.

[16] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 39
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.426) > However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[17] Identification of potential therapeutic target SPP1 and related RNA regulatory pathway in FECD through bioinformatics

• Authors: Fuji Deng, Zhixiang Yan, Jinpeng Li, Long-Fei Wu, Yong Liu et al.
• Year: 2026
• Venue: iScience
• URL: https://www.semanticscholar.org/paper/05c568392b6bdfd8f9e49f9f4cb0da6c906f6a89
• DOI: 10.1016/j.isci.2026.115591
• PMID: 42028016
• PMCID: 13099362
• Summary: It is proposed that SPP1 is a potential biomarker and therapeutic target for FECD, and the NEAT1/miR-181b-5p/SPP1 axis might be a regulatory RNA pathway involved in FECD development.
• Evidence snippets:
• Snippet 1 (score: 0.426) > Corneal blindness is the second leading cause of blindness globally, severely impacting the quality of life for tens of millions of people. Among the numerous corneal diseases, Fuchs' endothelial corneal dystrophy (FECD) is a common, age-related, and progressive posterior corneal disorder with a strong hereditary predisposition. 1 Its core pathophysiology is the functional failure of corneal endothelial cells (CECs). CECs form a non-regenerative monolayer on the posterior surface of the cornea and precisely regulate corneal stromal hydration through their ''pump-leak'' mechanism, thereby maintaining corneal transparency. 2 n patients with FECD, CEC density progressively declines, and cells exhibit morphological abnormalities (pleomorphism, polymegathism), accompanied by the formation of characteristic extracellular matrix (ECM) deposits known as guttae on Descemet's membrane. 3 The eventual loss of CEC function leads to stromal edema, decreased corneal transparency, and ultimately, severe vision loss. 4,5 tiological studies have revealed a highly complex genetic background for FECD. The abnormal expansion of a CTG trinucleotide repeat in an intron of the TCF4 gene is the most common and significant genetic risk factor. 6,7 Additionally, pathogenic mutations discovered in genes such as SLC4A11, ZEB1, and COL8A2 have provided important clues. 8,9 However, a critical knowledge gap remains: how are these upstream genetic variations translated into complex downstream cellular pathologies? Specifically, how do they drive CECs to undergo endothelial-tomesenchymal transition (EndMT), a process where CECs lose their epithelial characteristics and acquire mesenchymal properties, which is widely considered a core mechanism in guttae formation and corneal fibrosis 3 ? > Currently, no FDA-approved targeted drug is available globally that can effectively delay or reverse the course of the disease. 4 herefore, identifying and validating new therapeutic targets that can intervene in the disease process has become a pressing clinical need.

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Schnyder Corneal Dystrophy (SCD): Comprehensive Research Report

1. Disease Information

Overview: Schnyder corneal dystrophy (SCD; also historically "Schnyder crystalline corneal dystrophy," SCCD) is a rare, autosomal dominant, bilateral corneal stromal dystrophy characterized by progressive abnormal deposition of unesterified cholesterol and phospholipids in the corneal epithelium, Bowman's layer, and anterior/mid-stroma, leading to progressive corneal clouding and glare with disproportionate loss of photopic (bright-light) vision relative to scotopic vision. It was first described by Van Went and Wibaut (1924) and later characterized by Bernhard Schnyder (1929, 1939).

Key identifiers: - OMIM: #121800 — "SCHNYDER CORNEAL DYSTROPHY; SCCD" - MONDO: MONDO:0007374 - Orphanet: ORPHA:98967 - Gene: UBIAD1 (UbiA prenyltransferase domain containing 1), chromosome 1p36.22 (originally mapped to 1p34.1–p36) - IC3D classification: Category 1 anatomic (stromal) dystrophy — gene mapped and specific mutations known - HPO (suggested terms for phenotypic features, not the disease term itself): HP:0007957 (Corneal opacity), HP:0003124 (Hypercholesterolemia), HP:0002857 (Genu valgum) — see Phenotypes section for additional candidate terms

Synonyms: Schnyder crystalline corneal dystrophy; Schnyder crystalline dystrophy; central crystalline dystrophy of Schnyder; hereditary crystalline corneal dystrophy of Schnyder; SCCD; historically sometimes discussed with "hypercholesterolemia and genu valgum" as an associated triad, although these systemic findings are not obligate.

Data source type: Information below is derived from aggregated, peer-reviewed disease-level literature — case series/cohort natural-history studies (notably a retrospective series of 115 affected individuals from 34 families), molecular/mechanistic studies using patient-derived cells and mouse/zebrafish models, and curated reference databases (OMIM, Orphanet, ClinVar) — rather than raw individual-patient EHR data.

2. Etiology

Disease causal factor: SCD is caused by heterozygous, dominantly acting missense (and occasional other) variants in UBIAD1, which encodes a prenyltransferase enzyme with dual roles in vitamin K2 (menaquinone-4, MK-4) biosynthesis and regulation of cholesterol biosynthesis via HMG-CoA reductase (HMGCR). More than 20 distinct pathogenic UBIAD1 variants have been reported in SCD families worldwide (PMC2718742, PMC6142341).

Genetic risk factors: - Virtually all reported cases carry a heterozygous UBIAD1 missense variant; p.Asn102Ser (N102S), resulting from a recurrent c.305A>G transition, is described as a mutation "hotspot," having been independently identified in at least 10 unrelated families of Caucasian and Asian ancestry, consistent with a mutational hotspot rather than a single founder haplotype (PMID:18176953). - Other recurrent/well-characterized variants include p.Gly177Arg, p.Ala97Thr (de novo), p.Leu121Phe, p.Thr103Ile, p.Gly176Glu (novel), and p.Gly184Arg (mouse-modeled). - The disease-causing variant is essentially absent from population controls: "The mutation was not found in unaffected family members or in 144 Nova Scotian controls, 59 unrelated Caucasian CEPH HapMap DNA samples, or 89 unrelated Asian HapMap DNA samples" and was absent from additional 100 control samples (200 chromosomes) in other cohort analyses — consistent with a fully penetrant, rare, disease-causing allele rather than a common susceptibility variant. - No independently confirmed modifier genes have been established, though variable systemic lipid findings among carriers of the same mutation suggest background genetic modifiers of serum lipid handling may influence expressivity.

Environmental risk factors: No environmental, occupational, or infectious risk factors have been established as causal; SCD is a monogenic disorder. However, systemic dyslipidemia (whether coincidental or a modifier of local corneal lipid handling) has been reported in a substantial minority of patients and could theoretically modulate the rate of corneal deposit accumulation, though this is not established as causal.

Protective factors: None specifically identified. No protective genetic or environmental factors have been reported in the literature reviewed.

Gene-environment interactions: Not established. The mechanism (local corneal cholesterol accumulation driven by UBIAD1-mediated HMGCR stabilization) appears to be cell/tissue-intrinsic rather than dependent on systemic exposures, although systemic cholesterol status may be a covariate rather than a driver.

3. Phenotypes

SCD has a highly age-dependent, predictable clinical evolution documented in a landmark retrospective natural-history study of 115 affected individuals from 34 families (mean age at first exam 38.8 ± 20.4 years, range 2–81) (PMID:18427632; American Ophthalmological Society thesis, Weiss 2007).

Ocular phenotypes

Critical epidemiologic correction: Older literature emphasized crystals as a hallmark, but the large natural-history cohort found crystals in only 54% of affected patients ("crystalline" and "non-crystalline"/"acrystalline" forms exist) — a key reason the IC3D classification revised nomenclature, since roughly half of patients lacking visible crystals had been historically misdiagnosed.

Phenotype characteristics: - Age of onset: Highly variable — diagnosed as early as 17 months in some crystalline cases, but onset of visible corneal change in acrystalline (haze-predominant) disease may be delayed into the 4th decade. A de novo case showed corneal crystals at age 6. - Severity/progression: Progressive and predictable by age; patients are commonly stratified into <26 years, 26–39 years, and ≥40 years age bands for staging. "The configuration of the progressive corneal clouding is predictable on the basis of age." - Penetrance: Generally high but incomplete/age-dependent penetrance has been documented — e.g., a 19-year-old female carrying the family's disease haplotype and N102S variant (also present in her affected brother, father, and two paternal aunts) lacked clinical findings at that age, illustrating age-dependent expression. - Surgical morbidity by age: In the natural-history cohort, 29/115 patients underwent corneal surgery (5 PTK procedures in 3 patients; 39 penetrating keratoplasty [PKP] procedures in 27 patients); PKP was performed in 20/37 (54%) of patients ≥50 years and 10/13 (77%) of patients ≥70 years — "although excellent scotopic vision continues until middle age in SCCD, most patients had PKP by the 7th decade."

Systemic (non-ocular) phenotypes

Reported in a subset of patients, with variable expressivity even within the same family: - Hypercholesterolemia/dyslipidemia: "Mild dyslipidemia was found in all three individuals tested" in one cohort subset; elevated total cholesterol was documented in multiple probands (HP:0003124, Hypercholesterolemia). - Genu valgum / knee deformities: Reported in some families ("Proband 5 and her affected sister both had bilateral knee deformities, although their affected mother was normal," indicating variable expressivity) (HP:0002857, Genu valgum). - Other occasionally co-reported findings include scoliosis and, in isolated case reports, learning difficulties — these are not considered core, obligate features and their causal link to UBIAD1 dysfunction (vs. coincidence) remains unproven.

Quality-of-life impact: Primary impact is on daily visual function — glare-related disability under bright/photopic conditions, difficulty with tasks requiring fine visual acuity in daylight, and eventual need for corneal surgery in a majority of patients by their 60s–70s. Scotopic (night/dim-light) vision is relatively preserved for longer, which is somewhat atypical among corneal opacifying dystrophies and clinically important for counseling. No standardized disease-specific QOL instrument (e.g., EQ-5D-based) results were identified in the literature surveyed.

4. Genetic/Molecular Information

Causal gene: UBIAD1 (HGNC:19828; NCBI Gene ID: 84896), formerly known as TERE1. Chromosomal location 1p36.22.

Pathogenic variants: - Gene: UBIAD1 (specific isoform reference typically NM_013319.3) - Variant classification: The recurrent and well-studied variants (e.g., N102S/p.Asn102Ser, per ClinVar RCV000000904.3) are classified as Pathogenic for Schnyder crystalline corneal dystrophy. - Variant type: Almost exclusively missense variants clustering in transmembrane/active-site regions of the prenyltransferase domain — e.g., p.Asn102Ser (c.305A>G), p.Gly176Glu (c.527G>A, novel), p.Ala97Thr (c.289G>A, de novo), p.Leu121Phe (c.361C>T), p.Thr103Ile (c.308C>T), p.Gly177Arg, and the mouse-orthologous p.Gly184Arg. - Allele frequency: Essentially absent from large population reference datasets (gnomAD) and was not detected in multiple ethnically diverse control panels in the original discovery studies (144 Nova Scotian controls; 59 Caucasian and 89 Asian HapMap samples; additional 100-sample control panels) — consistent with a rare, highly penetrant dominant disease allele. - Somatic vs. germline: Germline; SCD is a heritable Mendelian disorder, though at least two independently confirmed de novo germline mutations have been reported (p.Ala97Thr being the second such observation in the literature) (PMID:27382485). - Functional consequence: Gain-of-function/dominant-negative-type mechanism at the protein-interaction level — disease-associated UBIAD1 variants are mislocalized (retained in the endoplasmic reticulum rather than trafficking normally) and gain an abnormal, stabilizing interaction with HMGCR, rather than simply losing enzymatic activity (see Mechanism section).

Modifier genes: None definitively established; phenotypic variability (e.g., presence/extent of crystals, systemic lipid/skeletal findings) among carriers of identical mutations suggests unidentified modifiers or stochastic/environmental factors.

Epigenetic information: No epigenetic mechanism (DNA methylation, histone modification) has been described as contributing to SCD pathogenesis in the literature surveyed; the disorder is understood as a classic monogenic, protein-interaction-mediated disease.

Chromosomal abnormalities: None reported; SCD is caused by point mutations, not large structural/chromosomal rearrangements.

Related gene biology: UBIAD1 is a bifunctional non-mitochondrial prenyltransferase: it (1) catalyzes conversion of menadione to menaquinone-4 (MK-4), the major tissue form of vitamin K2, and (2) in zebrafish and human cells contributes to non-mitochondrial coenzyme Q10 (CoQ10) biosynthesis (PMID:23169578). UBIAD1 (originally cloned as the prostate tumor suppressor TERE1) also has an established role restraining cholesterol synthesis in prostate cancer cells via SXR-nuclear-receptor-dependent gene regulation, and loss of TERE1/UBIAD1 expression is reported in ~50% of primary and metastatic prostate cancer specimens (PMID:23919967) — a distinct, disease-unrelated biological role of the same gene.

5. Environmental Information

SCD is a monogenic disorder with no established environmental, toxin, occupational, dietary, lifestyle, or infectious causal contributors identified in the literature reviewed. It is not a communicable or infectious disease. Systemic serum-lipid status is a co-reported (not clearly causal) covariate in a subset of patients. No CTD (Comparative Toxicogenomics Database)-type chemical-gene-disease interactions specific to SCD were identified via the searches performed for this report.

6. Mechanism / Pathophysiology

Causal chain (from molecular lesion to clinical phenotype)

1. Molecular trigger — UBIAD1 mislocalization: SCD-associated missense variants (e.g., N102S, G177R) cause UBIAD1 protein to be abnormally retained in the endoplasmic reticulum (ER) rather than trafficking normally to the Golgi.
2. Aberrant protein-protein interaction: ER-retained mutant UBIAD1 competes with Insig-1 for binding to HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the cholesterol biosynthetic (mevalonate) pathway. "SCD-associated mutants mainly resided in the endoplasmic reticulum (ER) and competed with Insig-1 for HMGCR binding, thereby preventing HMGCR from degradation and increasing cholesterol biosynthesis" (PMID:31323021, PLOS Genetics 2019).
3. Loss of HMGCR ER-associated degradation (ERAD): By displacing Insig-1, mutant UBIAD1 inhibits ERAD-mediated turnover of HMGCR, causing pathological HMGCR accumulation (confirmed both in patient-derived cells and in a Ubiad1^G184R/+ knock-in mouse model) (PMID:30785396, eLife 2019).
4. Increased local cholesterol biosynthesis: Stabilized HMGCR drives excess cholesterol synthesis in affected tissue (notably corneal keratocytes/fibroblasts).
5. Corneal cholesterol/phospholipid accumulation: Unesterified cholesterol, cholesterol esters, and phospholipids progressively deposit in the corneal epithelium, Bowman's layer, and anterior/mid-stroma, forming crystals in a subset of patients and diffuse haze in others.
6. Clinical manifestation: Progressive corneal opacification → glare/photopic visual loss → in advanced disease, surgical intervention (PTK or keratoplasty).

Parallel/contributing mechanism — vitamin K2 (MK-4) deficiency: Disease-associated UBIAD1 variants also show reduced menaquinone-4 (MK-4) synthetic activity, and their ER sequestration additionally protects the mutant protein from autophagy-mediated degradation, allowing intracellular accumulation that further amplifies HMGCR-ERAD inhibition (J Lipid Res, PMID pending verification — search-derived). Vitamin K2/MK-4 normally functions as a mitochondrial electron carrier supporting ATP production and membrane potential; the pathophysiologic significance of MK-4 deficiency specifically within corneal tissue (versus the HMGCR-stabilization arm) is less well defined and remains an area of ongoing mechanistic study.

Why statins are ineffective: "The efficacy of cholesterol-lowering statin therapy becomes limited, in part, because of UBIAD1-mediated inhibition of reductase ERAD" — i.e., because the disease mechanism operates downstream of/parallel to HMGCR transcriptional/enzymatic regulation (by blocking its degradation), systemic statin therapy does not correct the local corneal cholesterol-accumulation defect.

Cellular processes involved: ER protein quality control/ERAD, sterol-sensing/SREBP-Insig-HMGCR regulatory circuit, autophagy (mutant protein evades autophagic clearance), non-mitochondrial isoprenoid/vitamin K2 biosynthesis.

Cell types and anatomical structures implicated: Corneal epithelial cells, keratocytes (corneal stromal fibroblasts) — histopathology shows "abnormal accumulation of lipid and cholesterol in the central and paracentral basal epithelium, Bowman's layer, and superficial stroma," with deposits staining positive with Oil Red O and filipin (a fluorescent probe specific for unesterified cholesterol) (PMID:3303946).

Suggested GO terms: GO:0006695 (cholesterol biosynthetic process), GO:0034505 (sterol export from endoplasmic reticulum) / ERAD-related terms (e.g., GO:0030433, ER-associated ubiquitin-dependent protein catabolic process), GO:0042373 (vitamin K metabolic process).

Suggested CL terms: CL:0000575 (corneal epithelial cell), CL:0000138-type keratocyte/corneal stromal fibroblast term.

Molecular profiling / omics: No large-scale transcriptomic, proteomic, or single-cell atlases specific to human SCD corneal tissue were identified in this search; mechanistic insight instead derives from patient-derived skin fibroblast lipid-storage studies, biochemical reconstitution/structural studies of UBIAD1-HMGCR interaction, and the Ubiad1 knock-in mouse corneal phenotyping described below.

7. Anatomical Structures Affected

Organ level: - Primary organ: Cornea (both eyes — bilateral, generally symmetric). - Secondary/systemic involvement: In a subset of patients, systemic lipid metabolism (mild hypercholesterolemia/dyslipidemia) and skeletal system (genu valgum, occasionally scoliosis) — though these are not universal and their mechanistic link to UBIAD1 dysfunction outside the eye is not firmly established. - Body systems involved: Primarily the visual system (ocular); secondarily, in some patients, the musculoskeletal system and lipid/endocrine metabolism.

Tissue and cell level: - Corneal epithelium (basal layer), Bowman's layer, and anterior-to-mid corneal stroma are the principal sites of lipid deposition. - Keratocytes show intracellular and pericellular hyper-reflective deposits on confocal microscopy. - Corneal endothelium is typically spared.

Subcellular level: - Endoplasmic reticulum (site of mutant UBIAD1 retention and aberrant HMGCR stabilization). - Golgi apparatus (normal UBIAD1 trafficking destination, disrupted in mutants). - Mitochondria (site of vitamin K2/MK-4 electron-carrier function, relevant to the MK-4-deficiency arm of pathogenesis).

Suggested UBERON term: UBERON:0000966 (cornea); more specific substructure terms: UBERON:0001772 (corneal epithelium), UBERON:0004604 (Bowman's layer, if modeled), UBERON:0001773 (corneal stroma).

Localization: Bilateral and generally symmetric; central/paracentral cornea affected earliest, with a centrifugal/annular progression pattern (central haze/crystals → arcus lipoides at the periphery in the 3rd decade → mid-peripheral haze in the 4th decade and beyond).

8. Temporal Development

Onset: Congenital-to-childhood-onset in crystalline forms (documented as early as 17 months to age 6 in some kindreds); delayed, sometimes into the 4th decade, in acrystalline/haze-predominant presentations. Onset pattern is insidious and chronic, not acute.

Progression — staged, age-predictable natural history (Weiss et al., natural-history cohort of 115 patients/34 families): 1. Early stage (childhood–young adult): Central subepithelial/anterior stromal haze and/or crystal deposition. 2. Third decade: Appearance of arcus lipoides (premature peripheral corneal lipid ring), markedly earlier than typical age-related arcus senilis. 3. Late fourth decade onward: Mid-peripheral stromal haze develops, and central/paracentral opacification progressively worsens. 4. Later decades (50s–70s): Progressive photopic visual impairment; corneal surgery (PTK or keratoplasty) increasingly required — 54% of patients ≥50 years and 77% of patients ≥70 years in the cohort had undergone penetrating keratoplasty.

Progression rate: Slow and gradual over decades; "excellent scotopic vision continues until middle age," with photopic (glare-affected) vision declining disproportionately and earlier.

Disease course pattern: Chronic, progressive, non-remitting; no spontaneous remission has been described. No inflammatory/relapsing component.

Critical periods: Because staging is age-predictable, the literature emphasizes this as clinically useful for prognostication and surgical timing counseling, though it does not represent a "window" for disease-modifying intervention (no such intervention currently exists — see Treatment).

9. Inheritance and Population

Epidemiology: - SCD is classified as an ultra-rare disorder; Orphanet lists prevalence as unknown/not established. The literature explicitly states it is rare, with "less than 150 articles" in the published literature, and the largest reported natural-history cohort comprises 115 affected individuals across 34 families accumulated since 1989 at a single referral center — indicative of very low case ascertainment worldwide. - No formal population-based incidence or point-prevalence estimate (e.g., per 100,000) was identified in the sources reviewed; this should be recorded as UNKNOWN/NOT_YET_DOCUMENTED rather than estimated.

Inheritance pattern: Autosomal dominant.

Penetrance: High overall, but age-dependent — a documented case of a 19-year-old mutation/haplotype carrier (from a family with affected brother, father, and two paternal aunts) lacking clinical corneal findings at that age illustrates incomplete penetrance at younger ages, consistent with the broader age-staged natural history.

Expressivity: Variable — presence/extent of corneal crystals (54% of patients), degree of stromal haze, and presence/severity of systemic findings (dyslipidemia, genu valgum) vary substantially even within families carrying the identical mutation (e.g., discordant knee deformities between an affected mother and her affected daughters in one kindred).

Genetic anticipation: Not reported/established for SCD.

Germline mosaicism: Not specifically documented in the sources reviewed, though at least two confirmed de novo cases (new germline mutations, e.g., p.Ala97Thr) have been reported, underscoring that a negative family history does not exclude SCD.

Founder effects: No single, geographically restricted founder mutation/population has been established. Rather, the most common variant (N102S) is best characterized as a recurrent mutational hotspot, having arisen independently or been inherited in multiple unrelated Caucasian and Asian families, rather than tracing to one ancestral founder haplotype.

Consanguinity: Not specifically implicated as a risk factor, consistent with the autosomal dominant (not recessive) inheritance pattern.

Carrier frequency: Not established in general population databases; the pathogenic alleles are essentially absent from gnomAD and other large reference panels, consistent with high penetrance combined with rarity (rather than a "carrier" state as would apply to a recessive trait).

Population demographics: - Cases have been reported across diverse ancestries, including White American, White British, White Czech, South Asian, Han Chinese, and Saudi Arabian families — indicating SCD is not confined to a single ethnic group, though most large natural-history cohorts derive from North American/European referral populations. - No clear sex predilection (male:female ratio) was identified as skewed in the sources reviewed; both sexes are affected, consistent with autosomal (non-X-linked) dominant inheritance. - Age distribution of affected individuals in the largest cohort ranged from 2 to 81 years at presentation (mean 38.8 years), reflecting both pediatric-onset crystalline and adult-onset acrystalline presentations.

10. Diagnostics

Clinical tests: - Slit-lamp biomicroscopy: Primary diagnostic tool; identifies central corneal haze/opacity, crystalline deposits (in ~54% of patients), and arcus lipoides. - Anterior segment optical coherence tomography (AS-OCT/SD-OCT): Reveals "highly reflective deposits in the anterior stroma" and "a discontinuous hyper-reflective line beneath the epithelium," useful for both diagnosis and quantifying deposit depth/extent. - In vivo confocal microscopy: Identifies "small round deposits" in superficial epithelial cells, "hyper-reflective deposits within and around keratocytes," and needle-shaped/rectangular crystals in the anterior stroma, with normal basal epithelium and endothelium — useful in equivocal or acrystalline cases and in young children. - Serum lipid panel: Recommended given the reported association with dyslipidemia in a subset of patients (mild elevations in total cholesterol reported). - Histopathology (when tissue is available, e.g., post-PTK or keratoplasty specimens): Lipid/cholesterol deposits stain positive with Oil Red O and with filipin (fluorescent detection of unesterified cholesterol); electron microscopy confirms lipid/cholesterol accumulation in basal epithelium, Bowman's layer, and superficial stroma. Crystals are often birefringent under polarized light.

Genetic testing: - Approach: Given the small size of UBIAD1 (2 coding exons), Sanger sequencing of the coding regions is the standard, cost-effective diagnostic approach; targeted single-gene testing is typically sufficient given the well-characterized mutational spectrum, though broader corneal-dystrophy gene panels (including UBIAD1 alongside TGFBI and others) or exome sequencing may be used when the phenotype is atypical or a family history is absent. - Clinical utility: Genetic testing is valuable even without a positive family history, particularly for identifying de novo mutations, and can help distinguish acrystalline SCD from other causes of unexplained corneal haze. - No routine role for whole-genome sequencing, chromosomal microarray, karyotyping, FISH, mitochondrial DNA testing, or repeat-expansion testing has been described for SCD, consistent with its being a single-gene missense disorder without structural or expansion-type variants.

Clinical/diagnostic criteria and differential diagnosis: - Diagnosis is established by characteristic slit-lamp findings (with the important caveat that ~46% of patients lack crystals) and can be confirmed by molecular genetic testing and/or histopathology. - Differential diagnosis includes other conditions causing corneal crystalline deposits or opacity: Bietti crystalline dystrophy (a distinct retinal/corneal crystalline disorder, CYP4V2-related), lattice corneal dystrophy (TGFBI-related, linear branching amyloid), granular corneal dystrophy (TGFBI-related, sharply defined hyperreflective deposits), macular corneal dystrophy (diffuse stromal hyperreflectivity), cystinosis, tyrosinemia, hyperuricemia/gout, multiple myeloma/monoclonal gammopathy (paraproteinemic crystalline keratopathy), infectious crystalline keratopathy, Dieffenbachia keratitis, fish-eye disease, LCAT deficiency, and Tangier disease (the latter three being systemic lipid-metabolism disorders with corneal lipid deposition, which can be distinguished by systemic lipid-profile and genetic testing).

Screening: No population-based or newborn screening programs exist for SCD, consistent with its rarity and non-life-threatening ocular-only (typically) phenotype. Cascade screening (targeted clinical/genetic evaluation of at-risk relatives once a proband's mutation is known) is the appropriate approach, given autosomal dominant inheritance and documented age-dependent penetrance.

11. Outcome/Prognosis

Survival/mortality: SCD is not associated with reduced life expectancy or increased mortality; it is a purely (or predominantly) ocular disorder in most reported patients.

Morbidity and function: - Progressive photopic visual impairment and glare/photophobia are the dominant functional morbidities; scotopic (low-light) vision is comparatively preserved until middle age, an important prognostic/counseling point. - No standardized disease-specific quality-of-life instrument outcomes were identified in the literature surveyed.

Disease course / complications: - Progressive corneal opacification following the age-staged pattern described above (central haze/crystals → arcus lipoides in the 3rd decade → mid-peripheral haze in the 4th decade+). - Surgical morbidity increases with age: In the largest natural-history cohort, corneal surgery was performed in 29/115 patients; the proportion requiring penetrating keratoplasty (PKP) rose from 54% of patients ≥50 years to 77% of patients ≥70 years, with most patients requiring PKP by the 7th decade of life. - Recurrence after keratoplasty: A clinically important risk — disease can recur in corneal grafts, since the underlying metabolic/molecular defect is present throughout host tissue and is not "cured" by replacing the central cornea; this is a key reason PTK is often preferred as a first-line surgical option when feasible.

Prognostic factors: Age is the principal prognostic variable, given the highly predictable age-staged natural history; presence/absence of crystals does not appear to strongly predict long-term visual outcome, but degree of central stromal haze and cumulative deposit burden correlate with visual disability and surgical need.

12. Treatment

Pharmacotherapy: - Systemic lipid-lowering therapy (statins): Sometimes attempted empirically (e.g., in patients with concurrent dyslipidemia), but mechanistic studies indicate limited efficacy specifically for the corneal disease process, because SCD-associated UBIAD1 acts by inhibiting ER-associated degradation (ERAD) of HMGCR — i.e., stabilizing the very enzyme statins are designed to inhibit pharmacologically — such that "the efficacy of cholesterol-lowering statin therapy becomes limited, in part, because of UBIAD1-mediated inhibition of reductase ERAD." No disease-modifying pharmacotherapy targeting the corneal deposits currently exists. - No FDA-approved or guideline-endorsed disease-specific drug therapy exists for SCD as of current literature; management is predominantly procedural/surgical for visually significant disease. Suggested NCIT term if a general lipid-lowering agent is prescribed: NCIT:C15986 (Pharmacotherapy) + a specific statin therapeutic_agent (e.g., CHEBI-bound), though evidence for corneal benefit specifically is weak/absent.

Surgical/interventional: - Phototherapeutic keratectomy (PTK): Often the preferred first-line surgical option for visually significant anterior/subepithelial crystal or haze removal, in part because of the disease-recurrence risk associated with keratoplasty. Clinical series report meaningful visual gains — e.g., average best-corrected visual acuity improving from 20/175 to 20/40 under bright/glare conditions in one study, with subjective improvement in glare/photophobia in all treated patients. Limitations include progressive corneal thinning with repeated treatments, requiring pre-procedure pachymetry and a cap on the number of feasible PTK attempts. Suggested NCIT term: NCIT:C15329 (Surgical Procedure) or a more specific keratectomy term if available. - Penetrating keratoplasty (PKP) / deep anterior lamellar keratoplasty (DALK): Reserved for advanced disease or when PTK is insufficient/not feasible; effective for visual rehabilitation but carries a known risk of disease recurrence in the graft over time, since the systemic/cellular metabolic defect persists in the host and can affect donor tissue via host keratocyte repopulation or altered local lipid handling. NCIT term: NCIT:C15289 (Organ Transplantation) / a corneal-transplant-specific term where available.

Supportive care: Management of glare symptomatically (e.g., tinted lenses) in earlier disease stages before surgical intervention is warranted; routine ophthalmologic monitoring given the predictable, age-staged progression.

Experimental/investigational: No gene therapy, cell therapy, RNA-based therapy, or targeted molecular therapy directed at the UBIAD1-HMGCR-ERAD axis was identified as being in clinical development for SCD in the literature and search results reviewed; the elucidation of the ERAD-inhibition mechanism (PLOS Genetics 2019; eLife 2019) represents a plausible future therapeutic target (e.g., strategies to restore HMGCR ERAD or correct UBIAD1 ER retention) but remains at the basic/mechanistic research stage, primarily validated in the Ubiad1^G184R/+ mouse model.

Treatment outcomes / response rates: PTK series report substantial visual acuity improvement and glare reduction as above; no systematic large-scale trial data (e.g., NCT-registered interventional trials) for SCD were identified in the searches performed, consistent with the disease's rarity.

Treatment strategy / algorithm: General consensus reflected in the literature: monitor early/mild disease; consider PTK for visually significant anterior/subepithelial disease (preferred to reduce recurrence risk relative to keratoplasty); reserve PKP/DALK for advanced, PTK-refractory, or deep stromal disease, with counseling about graft-recurrence risk.

13. Prevention

Primary prevention: Not applicable in the traditional sense, since SCD is a fully genetically determined autosomal dominant disorder; there are no known modifiable environmental or lifestyle risk factors to intervene upon for primary prevention.

Secondary prevention (early detection): Given documented age-dependent penetrance and the existence of asymptomatic young mutation carriers, periodic ophthalmologic surveillance (slit-lamp exam, consider AS-OCT/confocal microscopy) of at-risk relatives in known SCD families is reasonable, allowing early detection of corneal changes and timely counseling about the expected age-staged disease course.

Tertiary prevention: Timely surgical intervention (PTK preferred over keratoplasty where feasible) to preserve visual function and to reduce disease-recurrence risk associated with keratoplasty; monitoring corneal thickness to time/limit repeated PTK procedures given progressive thinning risk.

Genetic counseling: Because SCD is autosomal dominant with a documented ~50% offspring transmission risk (subject to age-dependent penetrance), genetic counseling is appropriate for affected individuals and their families, including discussion of variable expressivity (a mutation carrier may have milder or more severe disease, or different crystal/haze predominance, than an affected parent or sibling) and the possibility of de novo mutation in apparently sporadic cases (no family history does not exclude the diagnosis).

Screening: No population-based or newborn screening program exists; cascade (family-based) clinical and/or genetic screening is the applicable model once a proband's causal variant is identified.

Public health / environmental interventions: Not applicable — SCD has no established environmental or infectious component.

14. Other Species / Natural Disease

Naturally occurring disease in other species: No confirmed naturally occurring, UBIAD1-orthologous corneal lipid-storage disease analogous to human SCD was identified in veterinary/OMIA literature during this search. SCD-like corneal crystalline conditions have been described anecdotally in some domestic species (e.g., certain corneal dystrophies in dogs), but these are generally attributed to distinct genetic loci and are not established as UBIAD1-orthologous; this should be treated as not confirmed rather than asserted.

Comparative biology / evolutionary conservation: UBIAD1 orthologs are functionally conserved across vertebrates (mouse, zebrafish) with conserved roles in non-mitochondrial CoQ10 and vitamin K2 (MK-4) biosynthesis, and the protein is essential for embryonic development — "Ubiad1-deficient mouse embryos failed to survive beyond embryonic day 7.5," underscoring an essential, non-redundant developmental role for the gene beyond its cornea-specific disease relevance in humans (PMID reference: PLOS ONE 2014, Vitamin K2 Biosynthetic Enzyme UBIAD1 Is Essential for Embryonic Development of Mice).

Zoonotic potential / transmission: Not applicable — SCD is a non-infectious, monogenic disorder.

15. Model Organisms

Mouse models

• Heterozygous knock-in mouse, Ubiad1^G184R/+ (mouse ortholog of a human SCD variant): Because complete germline Ubiad1 knockout is embryonic lethal ("homozygous germ-line elimination of the Ubiad1 gene caused embryonic lethality"), researchers generated a heterozygous knock-in carrying the disease-associated missense change. Phenotype recapitulation: "Aged heterozygous Ubiad1 G184R/+ mice exhibited corneal opacification and free cholesterol accumulation, phenocopying clinical manifestations of SCD patients" — corneas from aged knock-in mice show opacification and sterol over-accumulation, successfully recapitulating key human disease features, and the model additionally demonstrated tissue accumulation of HMGCR due to inhibited ERAD, directly supporting the human mechanistic model (PMID:30785396, eLife 2019; PLOS Genetics 2019, PMID:31323021).
• A related N100S point-mutation mouse model has also been reported (Sci Rep 2018) as a model of SCD, complementing the G184R line.
• Model limitations: As an aged, heterozygous, single-tissue-focused model, the mouse system captures corneal opacification/cholesterol accumulation but does not fully model the human age-staged progression (central crystals → arcus lipoides → mid-peripheral haze) nor the variable systemic (dyslipidemia, skeletal) manifestations seen in some human patients; crystal formation specifically (versus diffuse opacification/cholesterol accumulation) has not been emphasized as a mouse phenotype in the sources reviewed.

Zebrafish models

Zebrafish ubiad1 mutants have been used primarily to dissect the gene's CoQ10/vitamin K2 and cardiovascular/antioxidant functions, rather than to model the corneal phenotype specifically: - barolo (bar) — a null ubiad1 allele — shows cardiovascular failure due to oxidative stress/ROS-mediated cellular damage, with depleted cytosolic CoQ10 levels and increased lipid peroxidation in vascular cells (relevant to UBIAD1's non-mitochondrial CoQ10 biosynthetic role). - reddish (reh, ubiad1^S587^) — develops a functional vasculature by 24–36 hours post-fertilization but subsequently shows cranial vascular hemorrhage/degeneration by 48 hpf due to loss of UBIAD1-dependent vitamin K2 (not rescued by exogenous CoQ10), demonstrating that the vitamin K2-synthesis function specifically (not just CoQ10) is essential for vascular endothelial homeostasis. - Applications/limitations: These zebrafish models have been valuable for dissecting UBIAD1's fundamental prenyltransferase biochemistry and its essential roles in vascular development and antioxidant defense (via CoQ10/eNOS regulation, PMID:23374346), but do not directly model the corneal/ophthalmic SCD phenotype — a limitation to note explicitly when using zebrafish data to support corneal pathophysiology claims; this would be an appropriate HUMAN_MODEL_MISMATCH-type caveat if curated into a mechanism-module framework, since the model demonstrates UBIAD1 biochemical/vascular biology but not corneal cholesterol deposition specifically.

Cellular models

• Patient-derived skin fibroblasts have historically been used to demonstrate abnormal lipid storage/handling in SCD patients, predating the identification of UBIAD1 as the causal gene (PMID:9450854, describing "evidence of abnormal lipid storage in skin fibroblasts").
• HEK293/transfected cell systems have been used extensively in the mechanistic dissection of the UBIAD1-Insig-1-HMGCR interaction and structural characterization of disease-associated variant effects on this interaction (bioRxiv structural study; PLOS Genetics 2019).

Summary of Key Ontology Term Suggestions for KB Curation

Note on unverified/tentative terms: The precise current HPO CURIEs for "corneal crystals" and "corneal arcus/arcus lipoides" were not definitively confirmed against a live HPO browser query during this research session and should be independently verified (e.g., via OAK/runoak) before being committed to a curated knowledge base entry, per standard anti-hallucination practice.

Sources

• Entry - #121800 - SCHNYDER CORNEAL DYSTROPHY; SCCD - OMIM
• Orphanet: Schnyder corneal dystrophy
• Schnyder Corneal Dystrophy - EyeWiki
• Schnyder corneal dystrophy and associated phenotypes caused by novel and recurrent mutations in the UBIAD1 gene - PMC
• Schnyder corneal dystrophy-associated UBIAD1 mutations cause corneal cholesterol accumulation by stabilizing HMG-CoA reductase - PLOS Genetics
• Schnyder corneal dystrophy-associated UBIAD1 inhibits ER-associated degradation of HMG CoA reductase in mice - eLife
• UBIAD1 Mutation Alters a Mitochondrial Prenyltransferase to Cause Schnyder Corneal Dystrophy - PMC
• A Mouse Model of Schnyder Corneal Dystrophy with the N100S Point Mutation - Scientific Reports
• The UBIAD1 prenyltransferase links menaquinone-4 synthesis to cholesterol metabolic enzymes - PubMed
• Genetic analysis of 14 families with Schnyder crystalline corneal dystrophy reveals clues to UBIAD1 protein function - Wiley
• Visual morbidity in thirty-four families with Schnyder crystalline corneal dystrophy (an American Ophthalmological Society thesis) - PubMed
• Identification of the First De Novo UBIAD1 Gene Mutation Associated with Schnyder Corneal Dystrophy - PubMed
• Clinical diversity in patients with Schnyder corneal dystrophy—a novel and known UBIAD1 pathogenic variants - PMC
• Schnyder Corneal Dystrophy in a Saudi Arabian Family with Heterozygous UBIAD1 Mutation (p.L121F) - PMC
• A novel UBIAD1 mutation identified in a Chinese family with Schnyder crystalline corneal dystrophy - PMC
• Unesterified Cholesterol in Schnyder's Corneal Crystalline Dystrophy - PubMed
• Multimodal Imaging Features of Schnyder Corneal Dystrophy - PMC
• Management of Stromal Corneal Dystrophies; Review of the Literature with a Focus on Phototherapeutic Keratectomy and Keratoplasty - PMC
• Phototherapeutic keratectomy in Schnyder crystalline corneal dystrophy - PubMed
• Schnyder Corneal Dystrophy Differential Diagnoses - Medscape
• The IC3D Classification of the Corneal Dystrophies - Cornea Society
• NM_013319.3(UBIAD1):c.305A>G (p.Asn102Ser) AND Schnyder crystalline corneal dystrophy - ClinVar
• The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer - PMC
• Vitamin K2 Biosynthetic Enzyme, UBIAD1 Is Essential for Embryonic Development of Mice - PLOS ONE
• Ubiad1 Is an Antioxidant Enzyme that Regulates eNOS Activity by CoQ10 Synthesis - PMC
• Animal Models of Coenzyme Q Deficiency: Mechanistic and Translational Learnings - PMC
• Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation - Journal of Lipid Research
• Case Report of Schnyder Corneal Dystrophy—A Rare Lipid Metabolic Disorder of the Cornea - PMC